中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(6): 1288-1292

Diagnostic accuracy of FibroScan-AST score in nonalcoholic steatohepatitis with significant activity and fibrosis

DOI: 10.3969/j.issn.1001-5256.2022.06.014

  • Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

More Information
  • Corresponding author: GUI Honglian, ghl11535@rjh.com.cn (ORCID:0000-0003-3624-4800)
  • Received Date: 2021-10-27
  • Accepted Date: 2021-11-29
  • Published Date: 2022-06-20
    Abstract
  •   Objective  To investigate the diagnostic accuracy of FibroScan-AST (FAST) score in patients with high-risk nonalcoholic steatohepatitis (NASH) with a nonalcoholic fatty liver disease (NAFLD) activity score of ≥4 and significant liver fibrosis (F ≥2), along with comparison with other serological models.  Methods  A total of 84 consecutively admitted patients hospitalized in Ruijin Hospital from January 2015 to December 2020 and biopsy-confirmed NAFLD/NASH were included in this study, and FibroScan (liver stiffness measurement and controlled attenuation parameter) and blood biochemical tests were performed at one week before and after liver biopsy. A Kruskal-Wallis H analysis of variance was used for comparison between multiple groups, and Spearman's correlation coefficient was used to analyze the correlation between variables. The receiver operating characteristic (ROC) curve was plotted with pathological results as the "gold standard", and the area under the ROC curve (AUC) was calculated. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and classification accuracy were calculated based on the cut-off values determined by previous studies. In subgroup analysis, the patients were divided into subgroups based on different clinical indices to evaluate the diagnostic accuracy of each model, which was expressed as AUC (95% confidence interval [CI]).  Results  Among the 84 patients, 43 had high-risk NASH. The FAST score was 0.54(0.04-0.93) for all patients, and the FAST score for liver fibrosis stages F0-F4 was 0.26(0.06-0.73), 0.48(0.04-0.82), 0.61(0.13-0.75), 0.64(0.09-0.93), and 0.82(0.75-0.89), respectively, with a significant difference between stages (H=23.360, P < 0.001). FAST score was positively correlated with liver fibrosis stage (r=0.491, P < 0.001). NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4), and aspartate aminotransferase-to-platelet ratio index were positively correlated with liver fibrosis stage (r=0.230, 0.346, and 0.281, all P < 0.05), with a weaker correlation than FAST score. FAST score had an AUC of 0.725 (95%CI: 0.617-0.834, P < 0.001) in evaluating high-risk NASH. According to the low cut-off value determined by previous studies, FAST score ≤0.35 excluded high-risk NASH in 21 patients (25%) with an NPV of 71%; according to the high cut-off value, FAST score ≥0.67 helped to make a confirmed diagnosis of high-risk NASH in 19 patients (22.6%) with a PPV of 74%. NFS and FIB-4 had an AUC of 0.633(95%CI: 0.513-0.753) and 0.686(95%CI: 0.570-0.803), respectively, in the diagnosis of high-risk NASH (P < 0.05).  Conclusion  FAST score can accurately determine the presence or absence of high-risk NASH in NAFLD patients with or without metabolic risk factors, and selection of appropriate cut-off values can help some patients avoid liver biopsy.

     

    • FullText(HTML)
  • loading
    • References(11)
  • [1]
    ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
    [2]
    KLEINER DE, BRUNT EM, WILSON LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2019, 2(10): e1912565. DOI: 10.1001/jamanetworkopen.2019.12565.
    [3]
    NEWSOME PN, SASSO M, DEEKS JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4): 362-373. DOI: 10.1016/S2468-1253(19)30383-8.
    [4]
    ANSTEE QM, LAWITZ EJ, ALKHOURI N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: Baseline data from the STELLAR trials[J]. Hepatology, 2019, 70(5): 1521-1530. DOI: 10.1002/hep.30842.
    [5]
    SIDDIQUI MS, YAMADA G, VUPPALANCHI R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage[J]. Clin Gastroenterol Hepatol, 2019, 17(9): 1877-1885. e5. DOI: 10.1016/j.cgh.2018.12.031.
    [6]
    KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41(6): 1313-1321. DOI: 10.1002/hep.20701.
    [7]
    HARRISON SA, RATZIU V, BOURSIER J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(11): 970-985. DOI: 10.1016/S2468-1253(20)30252-1.
    [8]
    EDDOWES PJ, SASSO M, ALLISON M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156(6): 1717-1730. DOI: 10.1053/j.gastro.2019.01.042.
    [9]
    OEDA S, TAKAHASHI H, IMAJO K, et al. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes[J]. Hepatol Res, 2020, 50(7): 831-839. DOI: 10.1111/hepr.13508.
    [10]
    POYNARD T, MUNTENAU M, MORRA R, et al. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: A 2008 update[J]. Gastroenterol Clin Biol, 2008, 32(6 Suppl 1): 8-21. DOI: 10.1016/S0399-8320(08)73990-3.
    [11]
    BRIL F, MCPHAUL MJ, CAULFIELD MP, et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes[J]. Diabetes Care, 2020, 43(2): 290-297. DOI: 10.2337/dc19-1071.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1013) PDF downloads(125) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return